Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 13 jan 2016 - 07:47

Statutaire naam Galapagos NV

Titel Galapagos and Gilead cleared by US FTC to close their global partnership on filgotinib

Bericht Mechelen, Belgium and Foster City, CA, USA; 13 January 2016: Galapagos NV (Euronext & NASDAQ: GLPG) and Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the U.S. Federal Trade Commission ("FTC") provided early termination of the waiting period for their global partnership agreement on filgotinib under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The deal is expected to close by the end of the month. Upon closing, Galapagos will receive an upfront license fee of $300 million and Gilead will make a $425 million equity investment in Galapagos by subscribing for shares at a price of €58 per share. After the issuance of the shares, Gilead will own approximately 15 percent of the outstanding share capital of Galapagos, depending on the $/€ exchange rate at closing.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201601130000000002_Galapagos and Gilead cleared by US FTC to close their global partnership on filgotinib.pdf (opens in a new window)

201601130000000002_Galapagos en Gilead krijgen toestemming van de US FTC om hun wereldwijde overeenkomst voor filgotinib af te ronden.pdf (opens in a new window)

Datum laatste update: 01 september 2024